➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Tesetaxel

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Tesetaxel?

Tesetaxel is an investigational drug.

There have been 16 clinical trials for Tesetaxel. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2017.

The most common disease conditions in clinical trials are Breast Neoplasms, Stomach Neoplasms, and Melanoma. The leading clinical trial sponsors are Genta Incorporated, Odonate Therapeutics, Inc., and Odonate Therapeutics, LLC.

There are six hundred and twenty-nine US patents protecting this investigational drug and five international patents.

Recent Clinical Trials for Tesetaxel
The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid TumorsOdonate Therapeutics, Inc.Phase 1
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Patients With HER2 Negative MBCOdonate Therapeutics, Inc.Phase 2
Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBCOdonate Therapeutics, Inc.Phase 2

See all Tesetaxel clinical trials

Clinical Trial Summary for Tesetaxel

Top disease conditions for Tesetaxel
Top clinical trial sponsors for Tesetaxel

See all Tesetaxel clinical trials

US Patents for Tesetaxel

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tesetaxel   Get Started Free Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC)   Get Started Free
Tesetaxel   Get Started Free Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Get Started Free
Tesetaxel   Get Started Free Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)   Get Started Free
Tesetaxel   Get Started Free Pyrrolidinone derivatives as MetAP-2 inhibitors Merck Patent GmbH (Darmstadt, DE)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tesetaxel

Drugname Country Document Number Estimated Expiration Related US Patent
Tesetaxel World Intellectual Property Organization (WIPO) WO2015148714 2034-03-25   Get Started Free
Tesetaxel Australia AU2015231053 2034-03-21   Get Started Free
Tesetaxel Brazil BR112016021620 2034-03-21   Get Started Free
Tesetaxel Canada CA2943339 2034-03-21   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.